

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR PTA BALLOON CATHETER — LARGE DIAMETER IN CHINA

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce on April 12, 2022, that our PTA Balloon Catheter — Large Diameter, independently developed in-house by the Company, has been granted the marketing approval by the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) for the Percutaneous Transluminal Angioplasty (PTA) in the peripheral vasculature as planned. It marks the first domestically developed PTA Balloon Catheter — Large Diameter product that has ever been approved by NMPA and is the second NMPA approval that the Company has obtained in 2022.

This product is developed and manufactured on our balloon forming and manufacturing platform on which we have produced all our balloon catheter products with consistent high quality and efficiency. The product has several outstanding features: (1) the unique tapered head end and short shoulder design which can maximize the protection of normal blood vessels even for tortuous lesions; (2) the braided delivery rod demonstrates excellent crossing capability; and (3) the fluoroscopic visualization ensures accurate positioning of the balloon during procedures. Additionally, the product is expected to deliver outstanding filling performance and it has wide-ranging specifications for different clinical demand. We expect this newly launched product to show advantages in the treatment of various vascular diseases, such as iliac vein compression syndrome and other peripheral vascular occlusion.

When this product is properly used in combination with mechanical thrombectomy devices, drug-coated balloons and peripheral stents, we expect to see better long-term treatment efficacy.

The successful launch of this product positions the Company as the first domestic company that can provide comprehensive peripheral balloon catheter product offerings including Ultrafree® Drug Coated PTA Balloon Catheter, PTA Balloon Catheter and High Pressure PTA Balloon Catheter, covering both arterial and venous diseases treatments. We believe with the launch of this product we can better address the unmet clinical needs of domestic patients.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 12, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji., Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.